- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–13
of 13
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Antiphospholipid Antibody Syndrome, End Stage Renal Disease
- Interventions
- Eculizumab
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Carcinoma, Non-small-Cell Lung
- Interventions
- Amivantamab, Lazertinib, Carboplatin, Pemetrexed, Direct Oral Anticoagulant (DOAC), Low Molecular Weight Heparin (LMWH)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 26
- States / cities
- La Jolla, California • Orange, California • Stanford, California + 21 more
- Conditions
- Septic Shock, Vasodilatory Shock
- Interventions
- Unfractionated heparin, Venous thromboprophylaxis (VTE)
- Drug · Other
- Lead sponsor
- University of Manitoba
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- New Onset Atrial Fibrillation, Sepsis, Respiratory Failure
- Interventions
- Amiodarone in Parenteral Dosage Form, Amiodarone Pill, Direct Current Cardioversion (DCC), Rate-control therapy
- Drug · Procedure
- Lead sponsor
- Our Lady of the Lake Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Lazertinib, Amivantamab, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 701 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 12 more
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- discontinue anticoagulation therapy, Anticoagulant drugs, Catheter Ablation
- Behavioral · Drug · Procedure
- Lead sponsor
- China National Center for Cardiovascular Diseases
- Government
- Eligibility
- 18 Years and older
- Enrollment
- 3,160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Upper Gastrointestinal Bleeding
- Interventions
- Clinician notification, Clinician Notification with Nurse Facilitation, Clinician Notification / Patient Activation, Clinician Notification with Nurse Facilitation / Patient Activation
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Aortic-valve Replacement
- Interventions
- 4D Cardiac CT Scan, LivaNova Bioprothetic Aortic Valve Implant
- Diagnostic Test · Device
- Lead sponsor
- Corcym S.r.l
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 8
- States / cities
- Indianapolis, Indiana • Scarborough, Maine • Takoma Park, Maryland + 5 more
- Conditions
- Thromboembolic Events
- Interventions
- Not listed
- Lead sponsor
- Texas Cardiac Arrhythmia Research Foundation
- Other
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Stroke, Atrial Fibrillation
- Interventions
- Non-vitamin K oral anticoagulant (NOAC)
- Drug
- Lead sponsor
- Population Health Research Institute
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 2,270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Houston, Texas
- Conditions
- Atrial Fibrillation
- Interventions
- Drug (Direct thrombin or Factor Xa inhibitor)
- Other
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 6 more
- Conditions
- ECMO, Heparin, Respiratory Failure
- Interventions
- subcutaneous heparin anticoagulation
- Drug
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas